Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

BACKGROUND AND PURPOSE: Besides targeting the well-known oncogenic c-Met, crizotinib is the first oral tyrosine kinase inhibitor inhibiting anaplastic lymphoma kinase (ALK) in clinical trials for the treatment of non-small cell lung cancer. Here, we assessed the possible reversal of multidrug resist...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhou, Wen-jing, Zhang, Xu, Cheng, Chao, Wang, Fang, Wang, Xiao-kun, Liang, Yong-ju, To, Kenneth Kin Wah, Zhou, Wang, Huang, Hong-bing, Fu, Li-wu
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Publishing Ltd 2012
Materias:
Research Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3419910/
https://ncbi.nlm.nih.gov/pubmed/22233293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2012.01849.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares